共 50 条
The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib
被引:0
|作者:
Omran, Mervat M.
[1
]
Ibrahim, Amel B.
[2
]
Abdelfattah, Raafat
[3
]
Moussa, Heba S.
[4
]
Shouman, Samia A.
[1
]
Hamza, Marwa S.
[5
]
机构:
[1] Cairo Univ, NCI, Canc Biol Dept, Pharmacol Unit, Kasr Al Eini St, Cairo 11796, Egypt
[2] Zawia Univ, Fac Med, Dept Pharmacol, Az Zawiyah, Libya
[3] Cairo Univ, NCI, Med Oncol Dept, Cairo, Egypt
[4] Cairo Univ, NCI, Clin Pathol Dept, Cairo, Egypt
[5] British Univ Egypt, Fac Pharm, Clin Pharm Practice Dept, El Sherouk City, Cairo, Egypt
关键词:
Imatinib mesylate;
CML;
adherence;
trough;
peak;
CHRONIC MYELOGENOUS LEUKEMIA;
CYTOGENETIC RESPONSES;
TYROSINE KINASE;
BLAST CRISIS;
THERAPY;
NONADHERENCE;
OUTCOMES;
D O I:
10.1080/10428194.2024.2403671
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Chronic Myeloid Leukemia (CML) requires consistent medication adherence to Imatinib (IM) for optimal outcomes, however, adherence to oral chemotherapy is challenging. This observational study explores the relationship between patient knowledge, motivation, and adherence to IM therapy, and their collective impact on clinical outcomes. A prospective, observational study was conducted with 101 CML patients. The 6-Item Morisky Medication Adherence Scale (MMAS-6) was used to assess adherence, motivation, and knowledge levels. The study found that high motivation was significantly associated with lower BCR-ABL expression (p = 0.025). Patients with high knowledge and motivation had a 71% favorable response rate, compared to 0% in those with low knowledge and motivation (p = 0.01). As conclusion both patient motivation and knowledge are crucial for favorable treatment outcomes in CML. High levels of both significantly correlate with better clinical responses. Tailored interventions to enhance patient knowledge and motivation are essential.
引用
收藏
页码:123 / 130
页数:8
相关论文